Newcelx Ltd. - (NCEL) closed at $2.70 on October 28, 2026, down 1.5% from the previous close, on volume of 3,856 shares (30-day average 7,234).
Data as of October 28, 2026.
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Globe Newswire (Fri, 31-Jul 9:00 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Newcelx Ltd. - trades on the NASDAQ stock market under the symbol NCEL.
As of October 28, 2026, NCEL stock price declined to $2.70 with 3,856 million shares trading.
NCEL has a market cap of $15.60 million. This is considered a Sub-Micro Cap stock.
NCEL support price is $2.46 and resistance is $3.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCEL shares will trade within this expected range on the day.
